A Blood Test That Hints at Future Memory Problems
2021 Scientific Study
Original Paper: “A microRNA signature that correlates with cognition and is a target against cognitive decline”
Islam R., Kaurani L., et al. • EMBO Molecular Medicine • October 2021
What Was the Big Question?
Some people stay sharp as they age. Others develop memory problems that can lead to dementia or Alzheimer’s disease. The trouble is that by the time doctors notice these problems, a lot of damage has already happened in the brain — and current treatments often come too late to stop it.
Researchers wanted a simple, inexpensive way to spot people who might be heading toward cognitive decline—ideally years before obvious symptoms appear—so earlier help or future treatments could make a real difference.
What Are microRNAs?
MicroRNAs (often shortened to “miRNAs”) are tiny pieces of genetic material that act like volume controls for genes. They turn the production of certain proteins up or down. Because they circulate in the bloodstream and are very stable, scientists can measure them with a standard blood test.
Changes in just a few microRNAs can reflect many different processes happening inside the brain, which makes them promising candidates for early warning signals.
What Did the Researchers Discover?
After studying healthy young adults, older people with mild memory issues, and laboratory mice, the team identified a set of three specific microRNAs in the blood:
- miR-181a-5p
- miR-146a-5p
- miR-148a-3p
Together, these three form a “signature.” Higher levels of this signature in the blood were linked to poorer cognitive performance.
Key Findings in Everyday Language
- In healthy people: Those who performed better on memory and thinking tests tended to have lower levels of these three microRNAs in their blood.
- In aging mice: The levels of the three microRNAs rose in the blood before the mice showed clear memory problems—whether the decline was due to normal aging or an Alzheimer’s-like condition.
- In people with mild cognitive impairment (MCI): Those who had high levels of the signature were much more likely to go on to develop Alzheimer’s disease within about two years (roughly 90% in the high-level group in the study).
- What the microRNAs do: They appear to influence processes important for keeping brain cells healthy and communicating well. When their levels rise, it may signal that the brain’s “housekeeping” systems are under stress.
Can These microRNAs Be Targeted for Treatment?
Yes — at least in mice. The researchers used special molecules called “anti-miRs” that block or reduce the activity of these three microRNAs.
When they blocked the signature in older mice or in mice with Alzheimer’s-like brain changes, the animals showed improved learning and memory. This suggests the microRNAs are not just passive markers — they may actively contribute to the decline and could become targets for future RNA-based therapies.
Why This Matters
Today, most people are diagnosed with Alzheimer’s or related dementias only after significant brain changes have already occurred. A simple blood test that flags elevated levels of this three-microRNA signature could one day help identify people at higher risk while there is still time to intervene — through lifestyle changes, clinical trials, or future treatments.
Because the test uses blood rather than spinal fluid or expensive brain scans, it could potentially be used in routine check-ups as a screening tool. Those flagged could then receive more detailed testing.
Important Caveats
- This is one study. Larger and longer clinical trials in diverse human populations are still needed before any blood test based on this signature could be used in doctors’ offices.
- Having higher levels does not guarantee someone will develop dementia — it indicates increased risk.
- Blocking the microRNAs improved cognition in mice, but human therapies based on this approach are still experimental and years away.
- The signature reflects multiple biological processes, not just one specific disease pathway.
The Bottom Line
Scientists found three tiny RNA molecules in the blood whose levels rise as cognitive ability declines—often before obvious symptoms appear. Measuring them may eventually help identify people at higher risk of dementia earlier. In addition, reducing their activity improved memory in laboratory mice, opening a possible new avenue for treatment research.
This work represents a promising step toward earlier detection and potentially new RNA-based therapies for age-related cognitive decline and Alzheimer’s disease. This summary is written in plain language for educational purposes and is not a substitute for reading the original scientific paper.
